Bone Scan Software Accurately Calculates Prognosis of Advanced Prostate Cancer

Software captures key information related to survival and symptoms

Physician at computer
Article

A software tool designed to automatically calculate how extensively bones have been infiltrated by prostate cancer is both accurate and speedy, capturing key prognostic information related to survival and the development of symptoms over time.

The software, called the automated bone scan index (aBSI), was tested in a large, global multicenter study led by Duke Cancer Institute researchers. Findings from the phase 3 study were published May 17 in JAMA Oncology.

In the Duke-led study, 721 men with advanced, recurrent prostate cancer were evaluated using the aBSI software and followed for the duration of their care.

“This study describes major improvements over older techniques that doctors used to measure bone metastases to predict survival and help guide treatments for patients with advanced prostate cancer,” says lead author Andrew Armstrong, MD, associate director of the Duke Cancer Institute’s Prostate and Urologic Cancer Center.

The current method to measure bone metastases includes a CT or MRI scan along with a nuclear medicine test that involves a manual assessment of the bone metastases. Manual bone scan assessments using a formula based on bone mass and the number of cancer lesions can be done, but that process is both subjective and time-consuming, so is not used regularly in clinic. The aBSI software scans radiographic studies and quantifies the degree of bone metastases in a matter of seconds.

“It’s important to know how widespread metastatic disease is—both for patients to understand the likely course of their disease, and for doctors to determine the best potential treatments,” says Armstrong. ”It’s also a necessary point of reference in clinical trials, to understand whether investigational therapies are working and to quantify and predict possible outcomes.”

The researchers found that the aBSI technology was significantly better than the older, manual calculation at predicting survival time for the men, regardless of how widespread their bone metastases were. Added to other key clinical information, the technology provided prognostic information about patient outcomes and improved the ability to predict the time to symptom progression and the onset of pain.